We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

If this is friendly…

19 May 2014 By Chris Hughes

The U.S. drugmaker says it won’t go hostile for AstraZeneca, but has upped its non-binding takeover proposal to $117 bln, declared it “final” and slammed the board. The UK group is under real pressure to show it’s worth more. Yet Pfizer’s aggression is also an obstacle to talks.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)